Merck & Company Inc share price logo

Merck & Company Inc

NYSE: MRK

Mega Cap

$113.56

+0.41

(+0.36%)

as on

Merck & Company Inc Stock Performance

as on May 7, 2026 at 6:18 pm IST

  • Day's Low

    Day's High

    $112.74
    $114.48
    downward going graph

    0.72%

    Downside

    0.81%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $73.31
    $125.14
    downward going graph

    35.44%

    Downside

    10.20%

    Upside

    downward going graph

Merck & Company Inc share price movements today

Previous Close
$113.15
Open
$112.91
Volume
4.0M
Day's Low - High
$112.74 - $114.48
52 Week Low - High
$73.31 - $125.14

Merck & Company Inc Historical Returns

1 Month Return
-4.8 %
3 Month Return
-6.86 %
1 Year Return
+ 43.53 %
3 Year Return
-3.5 %
5 Year Return
+ 44.83 %

Merck & Company Inc Stock Fundamentals & Key Indicators

Check Merck & Company Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$280.5B

EPS (TTM)

5.0212

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.19%

PE Ratio (TTM)

31.99

Industry PE ratio

24.014285714285716

PEG Ratio

3.4586

EBITDA

29.5B

Revenue (TTM)

65.8B

Profit Margin

13.59%

Return On Equity TTM

18.94%

Merck & Company Inc Stock Valuation

Track how Merck & Company Inc P/E has moved over time to understand its valuation trends.

Merck & Company Inc in the last 5 years

  • Overview

  • Trends

Lowest (9.52x)

September 30, 2025

Industry (24.01x)

May 7, 2026

Today (31.99x)

May 7, 2026

Highest (69.20x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 31.99x

Merck & Company Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Merck & Company Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$280.5B44.83%31.9913.59%
BUY$281.0B243.65%27.3417.19%
BUY$880.2B405.09%35.0334.99%
BUY$364.6B77.13%101.035.79%
BUY$540.7B33.31%2621.83%

Stock Returns calculator for Merck & Company Inc Stock including INR - Dollar returns

The Merck & Company Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Merck & Company Inc investment value today

Current value as on today

₹1,61,073

Returns

₹61,073

(+61.07%)

Returns from Merck & Company Inc Stock

₹43,529 (+43.53%)

Dollar Impact

₹17,544 (+17.54%)

Analyst Recommendation on Merck & Company Inc Stock

Based on 31 analysts

BUY

87.10%

Buy

12.90%

Hold

0.00%

Sell

Based on 31 analysts, 87.1% of analysts recommend a 'BUY' rating for Merck & Company Inc. Average target price of $129.74

Merck & Company Inc Share Price Target

Get share price movements and forecasts by analysts on Merck & Company Inc.

What analysts predicted

12.47%UPSIDE

Target Price

$129.74

Current Price

$113.56

Analyzed by

31 Analysts

Target

$129.74

Merck & Company Inc target price $129.74, a slight upside of 12.47% compared to current price of $113.56. According to 31 analysts rating.

Indian Investors' Interest in Merck & Company Inc Stock

Investment in Merck & Company Inc Shares on INDmoney has grown by 126.17% in the last 30 days, indicating increased investment activity.

Time period: to

Change:126.17% versus previous 30 day period

Search interest for Merck & Company Inc Stock has increased by 75% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:75% versus previous 30 day period

Merck & Company Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
14,630
15,775
16,112
16,657
15,624
15,619
15,800
17,183
16,324
16,286
Gross Profit
10,718
12,235
12,367
12,577
11,796
11,734
11,953
12,989
11,507
13,342
Operating Income
-1,713
5,760
6,128
3,984
4,348
6,710
6,359
7,463
6,160
-1,884
EBITDA
-772
6,744
7,448
5,606
5,695
7,809
7,415
8,535
8,626
-1,884
Interest Expense
310
303
310
330
328
313
305
327
411
-
Depreciation
964
984
1,132
1,186
1,197
1,099
1,119
1,154
2,466
-
Income Before Tax
-2,046
5,670
6,006
4,090
4,170
5,903
4,999
6,745
3,420
-3,534
Income Tax Expense
-820
-
545
929
426
818
571
958
458
709
Net Income
-1,226
4,762
5,455
3,157
3,743
5,079
4,427
5,785
2,963
-4,240
Net Profit Margin
-8.38%
30.19%
33.86%
18.95%
23.96%
32.52%
28.02%
33.67%
18.15%
-26.03%

Merck & Company Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
64,926
Gross Profit
25,777
27,210
28,785
27,105
27,900
35,078
41,872
43,989
48,975
46,731
Operating Income
5,499
6,797
8,931
7,926
5,548
13,199
18,282
2,954
20,221
23,486
EBITDA
10,823
11,951
13,992
11,374
10,180
17,899
21,315
6,907
25,706
29,324
Interest Expense
693
754
772
893
831
806
962
1,146
1,271
1,357
Depreciation
-
4,637
4,519
3,652
3,625
3,214
3,909
3,800
4,499
5,838
Income Before Tax
4,659
6,521
8,701
7,171
5,863
13,879
16,444
1,889
19,936
21,067
Income Tax Expense
718
4,103
2,508
1,565
1,340
1,521
1,918
1,512
2,803
2,804
Net Income
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
Net Profit Margin
9.85%
5.97%
14.71%
25.16%
17.02%
26.79%
24.49%
0.61%
26.68%
28.12%

Merck & Company Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
4,767
5,461
3,161
3,744
5,085
4,429
5,787
2,963
-4,243
Operating Cash Flow
3,090
5,637
9,291
3,450
2,500
3,293
7,822
2,857
3,918
Investing Cash Flow
-1,376
-1,069
-3,845
-1,444
-1,487
-770
-283
-11,201
-10,210
Financing Cash Flow
-2,814
1,216
-2,425
-3,009
-5,755
-3,556
2,638
4,751
-2,981
Change in Cash
-1,238
5,702
3,315
-1,370
-4,586
-659
10,187
-3,514
-9,292

Merck & Company Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,418
6,193
9,777
7,082
12,358
14,526
365
17,133
18,254
Operating Cash Flow
6,447
10,922
13,440
10,253
14,109
19,095
13,006
21,468
16,472
Investing Cash Flow
2,679
4,314
-2,629
-9,443
-16,555
-4,960
-14,083
-7,734
-13,741
Financing Cash Flow
-10,006
-13,160
-8,861
-2,832
2,593
-9,119
-4,810
-7,032
-1,922
Change in Cash
-423
1,871
1,967
-1,769
14
4,606
-5,864
6,409
1,372

Mutual Funds that own Merck & Company Inc Stock

Check out the Mutual Funds with significant holdings in Merck & Company Inc.

Global Institutional Holdings in Merck & Company Inc

Funds
Holdings
Charles Schwab Investment Management Inc
1.97%
Goldman Sachs Group Inc
0.74%
Geode Capital Management, LLC
2.42%
BlackRock Inc
8.7%
JPMorgan Chase & Co
1.18%

Merck & Company Inc News & Key Events

  • img

    Today's Timeline - 06 May

    Wed, 06:30 PM

    -

    Merck Animal Health selects Agentforce Life Sciences for enhanced customer engagement across veterinary and animal farming channels.

    Wed, 07:46 PM

    -

    Merck's DCF analysis indicates it is undervalued by 47.2%, with an intrinsic value estimate of $214.43 per share.

    Thu, 00:25 AM

    -

    Morgan Stanley raises Merck's price target from $109 to $112 after Q1 results beat estimates, driven by Keytruda sales.

Insights on Merck & Company Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, ASTRAZENECA PLC has given 163.9% return, outperforming this stock by 120.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, ASTRAZENECA PLC has given 145.7% return, outperforming this stock by 149.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Merck & Co. Inc. has experienced a decline in revenue for the last three quarters, with figures dropping from $17.18 billion to $16.28 billion. This represents an average decrease of 2.6% per quarter.

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Merck & Co. Inc. has seen a decline in its net profit for the last three quarters. Starting from a profit of $5.78 billion, the net profit dropped significantly to -$4.24 billion. This represents an average decrease of 145.9% per quarter.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, MRK stock has moved down by -4.8%

About Merck & Company Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
OrganisationMerck & Company Inc
Headquarters126 East Lincoln Avenue, Rahway, NJ, United States, 07065
IndustryDrug Manufacturers - General
CEOMr. Robert M. Davis J.D.
E-voting on sharesClick here to vote

Key Management of Merck & Company Inc

Name

Title

Ms. Caroline A. Litchfield

Executive VP & CFO

Mr. Sanat Chattopadhyay

Executive VP & President of Merck Manufacturing Division

Mr. Dalton E. Smart III

Senior VP of Finance, Principal Accounting Officer & Global Controller

Mr. Peter Dannenbaum

Vice President of Investor Relations

Mr. Robert M. Davis J.D.

Chairman, President & CEO

Ms. Jennifer L. Zachary J.D.

Executive VP & General Counsel

Dr. Dean Y. Li M.D., Ph.D.

Executive VP & President of Merck Research Laboratories

Mr. David Michael Williams

Executive VP and Chief Information & Digital Officer

Mr. Chirfi Guindo

Executive Vice President of Strategic Access, Policy & Communications

Ms. Betty D. Larson

Executive VP & Chief Human Resources Officer

FAQs

What is Merck & Company Inc share price today?

Merck & Company Inc share price today is $113.56 as on at the close of the market. Merck & Company Inc share today touched a day high of $114.48 and a low of $112.74.

What is the 52 week high and 52 week low for Merck & Company Inc share?

Merck & Company Inc share touched a 52 week high of $125.14 on and a 52 week low of $73.31 on . Merck & Company Inc stock price today i.e. is closed at $113.56,which is 9.25% down from its 52 week high and 54.90% up from its 52 week low.

What is Merck & Company Inc's market capitalisation today?

Merck & Company Inc market capitalisation is $0.28T as on .

How to invest in Merck & Company Inc Stock (MRK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Merck & Company Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merck & Company Inc Shares that will get you 0.0132 shares as per Merck & Company Inc share price of $113.56 per share as on May 7, 2026 at 12:48 pm IST.

What is the minimum amount required to buy Merck & Company Inc Stock (MRK) from India?

Indian investors can start investing in Merck & Company Inc (MRK) shares with as little as ₹94.61 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.10 in Merck & Company Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Merck & Company Inc share’s latest price of $113.56 as on May 7, 2026 at 12:48 pm IST, you will get 0.0881 shares of Merck & Company Inc. Learn more about fractional shares .

What are the returns that Merck & Company Inc has given to Indian investors in the last 5 years?

Merck & Company Inc stock has given 44.83% share price returns and 29.19% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?